halometasone has been researched along with betamethasone-17-21-dipropionate* in 2 studies
2 trial(s) available for halometasone and betamethasone-17-21-dipropionate
| Article | Year |
|---|---|
A comparative multicentre trial of halometasone/triclosan cream and betamethasone dipropionate/gentamicin sulphate cream in the treatment of infected acute eczematous dermatitis.
A multicentre, between-patient, comparative trial was carried out to compare the efficacy and tolerability of a cream containing 0.05 halometasone and 1% triclosan with those of a cream with 0.05% betametasone dipropionate and 0.1% gentamicin sulphate in patients suffering from infected acute ezcematous dermatoses. In the evaluable trial population, consisting of 265 patients, halometasone/triclosan cream yielded a significantly (p = 0.001) higher success rate ('good' to 'very good' results), namely 96%, than the comparative cream (80%). Halometasone/triclosan cream also displayed a significantly (p = 0.008) higher cure rate (73.9%) than that observed with the comparative preparation (58.6%). The proportion of patients obtaining an early cure, i.e. in less than 20 days, was significantly (p = 0.0005) higher with halometasone/triclosan cream (42.5%) than with the comparative preparation (22.6%). The two preparations did not differ significantly with regard to the incidence and severity of adverse effects. Topics: Acute Disease; Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Clinical Trials as Topic; Drug Combinations; Eczema; Female; Gentamicins; Humans; Male; Middle Aged; Phenyl Ethers; Triclosan | 1983 |
[Comparative clinical trial of a new trihalogenated dermatocorticoid (halometasone) versus betamethasone dipropionate].
In a multicenter controlled study carried out in Austria and Switzerland by 8 dermatologists in 208 patients with acute eczematous dermatoses, 0.05% halometasone cream proved to have significantly superior clinical efficacy than 0.05% betamethasone dipropionate cream (P much less than 0.05) showing an equal tolerability. Good to very good results were reported in 93% of the patients treated with halometasone and in 84% of those treated with betamethasone dipropionate creams (Diprosone, Diproderm). General tolerability of both treatments was good. Neither skin atrophy nor any systemic adverse effect, due to the transcutaneous absorption of the corticoids, were observed in this study. Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Clinical Trials as Topic; Drug Tolerance; Eczema; Female; Glucocorticoids; Humans; Male; Middle Aged | 1983 |